pSivida Stock Price, News & Analysis (NASDAQ:PSDV)

$1.09 0.00 (0.00 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$1.09
Today's Range$1.05 - $1.12
52-Week Range$0.93 - $2.45
Volume228,010 shs
Average Volume379,721 shs
Market Capitalization$49.33 million
P/E Ratio-1.85
Dividend YieldN/A
Beta1.26

About pSivida (NASDAQ:PSDV)

pSivida logopSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert. Medidur is designed to treat chronic non-infectious uveitis affecting the posterior segment of the eye (posterior segment uveitis). ILUVIEN is an injectable micro-insert that provides treatment of DME from a single injection. Retisert is an implant that provides treatment of posterior segment uveitis. Its product development program is focused on utilizing its two technology platforms, Durasert and Tethadur, to deliver drugs and biologics to treat chronic diseases.

Receive PSDV News and Ratings via Email

Sign-up to receive the latest news and ratings for PSDV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:PSDV
CUSIPN/A
Phone+1-617-9265000

Debt

Debt-to-Equity RatioN/A
Current Ratio3.21%
Quick Ratio3.21%

Price-To-Earnings

Trailing P/E Ratio-1.84745762711864
Forward P/E Ratio-2.02
P/E GrowthN/A

Sales & Book Value

Annual Sales$7.54 million
Price / Sales6.54
Cash FlowN/A
Price / CashN/A
Book Value$0.22 per share
Price / Book4.95

Profitability

Trailing EPS($0.59)
Net Income$-18,480,000.00
Net Margins-882.37%
Return on Equity-205.82%
Return on Assets-144.60%

Miscellaneous

Employees22
Outstanding Shares45,260,000

pSivida (NASDAQ:PSDV) Frequently Asked Questions

What is pSivida's stock symbol?

pSivida trades on the NASDAQ under the ticker symbol "PSDV."

How were pSivida's earnings last quarter?

pSivida Corp. (NASDAQ:PSDV) issued its quarterly earnings results on Wednesday, February, 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.15) by $0.02. The firm earned $0.93 million during the quarter, compared to analyst estimates of $0.48 million. pSivida had a negative return on equity of 205.82% and a negative net margin of 882.37%. View pSivida's Earnings History.

When will pSivida make its next earnings announcement?

pSivida is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for pSivida.

Where is pSivida's stock going? Where will pSivida's stock price be in 2018?

7 Wall Street analysts have issued 1 year target prices for pSivida's shares. Their predictions range from $5.00 to $13.00. On average, they expect pSivida's share price to reach $7.57 in the next year. View Analyst Ratings for pSivida.

Who are some of pSivida's key competitors?

Who are pSivida's key executives?

pSivida's management team includes the folowing people:

  • David J. Mazzo Ph.D., Independent Chairman of the Board (Age 59)
  • Nancy S. Lurker, President, Chief Executive Officer, Independent Director (Age 58)
  • Leonard S. Ross, Vice President - Finance, Principal Financial Officer (Age 66)
  • Debora A. Jorn, Executive Vice President - Corporate and Commercial Development (Age 59)
  • James J. Barry Ph.D., Independent Director (Age 57)
  • Jay S. Duker M.D., Independent Director (Age 57)
  • Douglas Evan Godshall M.B.A., Independent Director (Age 51)
  • Kristine Peterson, Independent Director (Age 58)
  • Michael W. Rogers, Independent Director (Age 57)

Who owns pSivida stock?

pSivida's stock is owned by a number of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (3.37%), Geode Capital Management LLC (0.53%) and Essex Investment Management Co. LLC (0.35%). View Institutional Ownership Trends for pSivida.

Who bought pSivida stock? Who is buying pSivida stock?

pSivida's stock was bought by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, Geode Capital Management LLC and Renaissance Technologies LLC. View Insider Buying and Selling for pSivida.

How do I buy pSivida stock?

Shares of pSivida can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is pSivida's stock price today?

One share of pSivida stock can currently be purchased for approximately $1.09.

How big of a company is pSivida?

pSivida has a market capitalization of $49.33 million and generates $7.54 million in revenue each year. The company earns $-18,480,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. pSivida employs 22 workers across the globe.

How can I contact pSivida?

pSivida's mailing address is 480 Pleasant St Ste B300, WATERTOWN, MA 02472-2468, United States. The company can be reached via phone at +1-617-9265000 or via email at [email protected]


MarketBeat Community Rating for pSivida (PSDV)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  171 (Vote Outperform)
Underperform Votes:  99 (Vote Underperform)
Total Votes:  270
MarketBeat's community ratings are surveys of what our community members think about pSivida and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

pSivida (NASDAQ:PSDV) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.57$7.57$8.00$8.60
Price Target Upside: 570.04% upside588.31% upside577.97% upside418.07% upside

pSivida (NASDAQ:PSDV) Consensus Price Target History

Price Target History for pSivida (NASDAQ:PSDV)

pSivida (NASDAQ:PSDV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/8/2018HC WainwrightSet Price TargetBuy$5.00HighView Rating Details
12/15/2017B. RileySet Price TargetBuy$5.00MediumView Rating Details
12/11/2017Northland SecuritiesReiterated RatingBuy$10.00MediumView Rating Details
11/8/2017LaidlawInitiated CoverageBuy$5.00N/AView Rating Details
6/14/2017Ladenburg Thalmann Financial ServicesSet Price TargetBuy$13.00MediumView Rating Details
6/14/2017FBR & CoReiterated RatingBuyHighView Rating Details
5/30/2017Rodman & RenshawInitiated CoverageBuy$8.00HighView Rating Details
(Data available from 2/24/2016 forward)

Earnings

pSivida (NASDAQ:PSDV) Earnings History and Estimates Chart

Earnings by Quarter for pSivida (NASDAQ:PSDV)

pSivida (NASDAQ PSDV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018($0.15)N/AView Earnings Details
2/7/2018Q2 2018($0.15)($0.13)$0.48 million$0.93 millionViewListenView Earnings Details
11/7/2017Q1 2018($0.15)($0.15)$0.74 million$0.39 millionViewN/AView Earnings Details
9/11/2017Q4 2017($0.16)($0.16)$0.48 million$0.70 millionViewN/AView Earnings Details
5/4/2017Q3 2017($0.15)($0.15)$0.36 million$0.59 millionViewListenView Earnings Details
11/7/2016Q1($0.19)($0.21)$0.30 million$0.28 millionViewListenView Earnings Details
9/12/2016Q4($0.13)($0.19)$2.40 million$0.30 millionViewListenView Earnings Details
5/5/2016Q3($0.20)($0.15)$1.75 million$0.32 millionViewN/AView Earnings Details
2/8/2016Q2 2016($0.15)($0.18)$1.25 million$0.53 millionViewN/AView Earnings Details
11/5/2015Q116($0.15)($0.17)$0.50 million$0.47 millionViewN/AView Earnings Details
9/9/2015Q415($0.14)($0.17)$0.60 million$0.41 millionViewN/AView Earnings Details
5/8/2015Q315($0.13)($0.17)$0.33 millionViewN/AView Earnings Details
2/5/2015($0.13)($0.14)$0.52 millionViewN/AView Earnings Details
11/7/2014Q3 14($0.12)$0.67$25.30 millionViewN/AView Earnings Details
9/9/2014Q414($0.15)($0.15)$0.29 millionViewN/AView Earnings Details
5/13/2014Q314($0.15)($0.03)$0.55 million$2.00 millionViewN/AView Earnings Details
2/7/2014Q214($0.13)($0.13)$430.00 million$0.59 millionViewN/AView Earnings Details
11/12/2013Q1($0.14)$0.60 millionViewListenView Earnings Details
9/25/2013Q413($0.12)($0.17)$0.65 million$0.49 millionViewN/AView Earnings Details
5/13/2013Q3 2013($0.12)$0.51 millionViewN/AView Earnings Details
2/6/2013Q2 2013($0.11)$0.63 million$0.59 millionViewListenView Earnings Details
11/8/2012Q113($0.10)($0.11)ViewN/AView Earnings Details
9/24/2012Q4 2012($0.19)($0.11)ViewN/AView Earnings Details
5/9/2012Q3 2012($0.17)($0.13)ViewN/AView Earnings Details
2/8/2012Q2 2012($0.17)($0.13)ViewN/AView Earnings Details
11/7/2011Q1 2012($0.21)($0.12)ViewN/AView Earnings Details
9/12/2011Q4 2011($0.18)($0.01)ViewN/AView Earnings Details
5/10/2011Q3 2011($0.22)($0.13)ViewN/AView Earnings Details
2/9/2011Q2 2011$0.45($0.15)ViewN/AView Earnings Details
11/5/2010Q1 2011($0.14)($0.17)ViewN/AView Earnings Details
9/22/2010Q4 2010$0.68ViewN/AView Earnings Details
5/12/2010Q3 2010($0.19)($0.15)ViewN/AView Earnings Details
11/12/2009Q1 2010($0.09)ViewN/AView Earnings Details
9/24/2009Q4 2009($0.03)ViewN/AView Earnings Details
5/13/2009Q3 2009($0.04)ViewN/AView Earnings Details
2/11/2009Q2 2009($0.05)ViewN/AView Earnings Details
11/11/2008Q1 2009($0.03)ViewN/AView Earnings Details
9/26/2008Q4 2008($1.92)ViewN/AView Earnings Details
2/11/2008Q2 2008($0.04)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

pSivida (NASDAQ:PSDV) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20181($0.14)($0.14)($0.14)
Q3 20181($0.14)($0.14)($0.14)
Q4 20181($0.12)($0.12)($0.12)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for pSivida (NASDAQ:PSDV)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

pSivida (NASDAQ PSDV) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.49%
Institutional Ownership Percentage: 10.30%
Insider Trades by Quarter for pSivida (NASDAQ:PSDV)
Institutional Ownership by Quarter for pSivida (NASDAQ:PSDV)

pSivida (NASDAQ PSDV) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/14/2017Nancy LurkerInsiderBuy56,700$1.76$99,792.0056,700View SEC Filing  
1/4/2016Leonard S. RossVPSell5,000$4.70$23,500.00View SEC Filing  
12/22/2015Leonard S. RossVPSell33,950$5.39$182,990.50View SEC Filing  
12/22/2015Paul AshtonCEOSell120,000$5.39$646,800.00440,741View SEC Filing  
10/1/2014Paul AshtonCEOSell10,000$4.27$42,700.00View SEC Filing  
9/2/2014Paul AshtonCEOSell10,000$4.78$47,800.00View SEC Filing  
8/1/2014Paul AshtonCEOSell10,000$4.37$43,700.00View SEC Filing  
7/1/2014Paul AshtonCEOSell10,000$4.32$43,200.00View SEC Filing  
6/19/2014Paul AshtonCEOSell7,000$4.00$28,000.00View SEC Filing  
6/17/2014Lori FreedmanVPSell7,900$4.00$31,600.00View SEC Filing  
6/17/2014Paul AshtonCEOSell7,700$4.00$30,800.00View SEC Filing  
6/13/2014Lori FreedmanVPSell11,700$4.02$47,034.00View SEC Filing  
6/13/2014Paul AshtonCEOSell11,800$4.02$47,436.00View SEC Filing  
10/1/2012Paul HopperDirectorBuy10,000$1.68$16,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

pSivida (NASDAQ PSDV) News Headlines

Source:
DateHeadline
pSivida Corp. (PSDV) Given Consensus Recommendation of "Buy" by BrokeragespSivida Corp. (PSDV) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 16 at 1:36 AM
Whats Happening With These Generic Drugs Stocks? -- Neos Therapeutics, Pacira Pharma, pSivida, and Tetraphase ... - PR Newswire (press release)What's Happening With These Generic Drugs Stocks? -- Neos Therapeutics, Pacira Pharma, pSivida, and Tetraphase ... - PR Newswire (press release)
www.prnewswire.com - February 15 at 6:22 AM
Zacks: Analysts Expect pSivida Corp. (PSDV) to Announce -$0.13 EPSZacks: Analysts Expect pSivida Corp. (PSDV) to Announce -$0.13 EPS
www.americanbankingnews.com - February 15 at 3:16 AM
pSivida Corp. (PSDV) to Post Q3 2018 Earnings of ($0.14) Per Share, B. Riley ForecastspSivida Corp. (PSDV) to Post Q3 2018 Earnings of ($0.14) Per Share, B. Riley Forecasts
www.americanbankingnews.com - February 12 at 4:26 AM
pSivida to Present at the 2018 BIO CEO & Investor ConferencepSivida to Present at the 2018 BIO CEO & Investor Conference
finance.yahoo.com - February 9 at 3:29 PM
pSivida (PSDV) Given a $5.00 Price Target by HC Wainwright AnalystspSivida (PSDV) Given a $5.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - February 8 at 9:28 PM
pSivida (PSDV) Announces Quarterly  Earnings ResultspSivida (PSDV) Announces Quarterly Earnings Results
www.americanbankingnews.com - February 8 at 10:58 AM
pSivida (PSDV) Says Second Phase 3 Study for Durasert Three-year Treatment for Posterior Segment Uveitis ... - StreetInsider.compSivida (PSDV) Says Second Phase 3 Study for Durasert Three-year Treatment for Posterior Segment Uveitis ... - StreetInsider.com
www.streetinsider.com - February 8 at 6:08 AM
pSivida Corp. Reports Second Quarter FY2018 Results; Continues to Achieve Milestones and TimelinespSivida Corp. Reports Second Quarter FY2018 Results; Continues to Achieve Milestones and Timelines
finance.yahoo.com - February 8 at 6:08 AM
pSividas Second Phase 3 Study for Durasert™ Three-year Treatment for Posterior Segment Uveitis Maintains Positive Efficacy and Safety Profile at 12 MonthspSivida's Second Phase 3 Study for Durasert™ Three-year Treatment for Posterior Segment Uveitis Maintains Positive Efficacy and Safety Profile at 12 Months
finance.yahoo.com - February 8 at 6:08 AM
PSivida reports 2Q lossPSivida reports 2Q loss
finance.yahoo.com - February 8 at 6:08 AM
pSivida (PSDV) Set to Announce Quarterly Earnings on WednesdaypSivida (PSDV) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - January 31 at 1:52 AM
pSivida Corp. Announces Second Quarter Fiscal Year 2018 ... - GlobeNewswire (press release)pSivida Corp. Announces Second Quarter Fiscal Year 2018 ... - GlobeNewswire (press release)
globenewswire.com - January 24 at 3:25 PM
pSivida Corp. Announces Second Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call InformationpSivida Corp. Announces Second Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information
finance.yahoo.com - January 24 at 9:26 AM
pSivida Corp. (PSDV) Given Average Recommendation of "Buy" by AnalystspSivida Corp. (PSDV) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - January 22 at 1:40 AM
 Brokerages Anticipate pSivida Corp. (PSDV) Will Announce Quarterly Sales of $480,000.00 Brokerages Anticipate pSivida Corp. (PSDV) Will Announce Quarterly Sales of $480,000.00
www.americanbankingnews.com - January 14 at 12:34 PM
BRIEF-pSivida Submits New Drug Application For Durasert Three-Year Treatment For Posterior Segment Uveitis To The U.S. FDABRIEF-pSivida Submits New Drug Application For Durasert Three-Year Treatment For Posterior Segment Uveitis To The U.S. FDA
www.reuters.com - January 8 at 10:22 AM
pSivida Submits New Drug Application (NDA) for Durasert™ Three-Year Treatment for Posterior Segment Uveitis to the U.S. FDApSivida Submits New Drug Application (NDA) for Durasert™ Three-Year Treatment for Posterior Segment Uveitis to the U.S. FDA
finance.yahoo.com - January 8 at 10:22 AM
pSivida (PSDV) Secures Waiver from FDA for New Drug Application Filing FeepSivida (PSDV) Secures Waiver from FDA for New Drug Application Filing Fee
www.streetinsider.com - January 4 at 4:41 PM
pSivida to Present at the Annual Biotech Showcase ConferencepSivida to Present at the Annual Biotech Showcase Conference
finance.yahoo.com - January 2 at 5:34 PM
Zacks: Brokerages Anticipate pSivida Corp. (PSDV) Will Post Quarterly Sales of $480,000.00Zacks: Brokerages Anticipate pSivida Corp. (PSDV) Will Post Quarterly Sales of $480,000.00
www.americanbankingnews.com - December 28 at 6:40 AM
pSivida Corp. (PSDV) Given Average Rating of "Buy" by AnalystspSivida Corp. (PSDV) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - December 28 at 1:38 AM
 Analysts Anticipate pSivida Corp. (PSDV) to Post -$0.15 EPS Analysts Anticipate pSivida Corp. (PSDV) to Post -$0.15 EPS
www.americanbankingnews.com - December 26 at 5:24 PM
ETFs with exposure to pSivida Corp. : December 22, 2017ETFs with exposure to pSivida Corp. : December 22, 2017
finance.yahoo.com - December 22 at 7:40 PM
B. Riley Analysts Give pSivida (PSDV) a $5.00 Price TargetB. Riley Analysts Give pSivida (PSDV) a $5.00 Price Target
www.americanbankingnews.com - December 15 at 9:18 PM
pSivida (PSDV) Given a $5.00 Price Target at HC WainwrightpSivida (PSDV) Given a $5.00 Price Target at HC Wainwright
www.americanbankingnews.com - December 15 at 12:04 PM
HSS and pSivida Report Positive Phase 1 Knee Osteoarthritis Pain Study DataHSS and pSivida Report Positive Phase 1 Knee Osteoarthritis Pain Study Data
finance.yahoo.com - December 14 at 10:23 AM
ETFs with exposure to pSivida Corp. : December 11, 2017ETFs with exposure to pSivida Corp. : December 11, 2017
finance.yahoo.com - December 11 at 4:50 PM
pSivida (PSDV) Rating Reiterated by Northland SecuritiespSivida (PSDV) Rating Reiterated by Northland Securities
www.americanbankingnews.com - December 11 at 12:34 PM
-$0.15 Earnings Per Share Expected for pSivida Corp. (PSDV) This Quarter-$0.15 Earnings Per Share Expected for pSivida Corp. (PSDV) This Quarter
www.americanbankingnews.com - December 9 at 1:20 AM
pSivida Corp. (PSDV) Forecasted to Post Q2 2018 Earnings of ($0.14) Per SharepSivida Corp. (PSDV) Forecasted to Post Q2 2018 Earnings of ($0.14) Per Share
www.americanbankingnews.com - December 6 at 12:02 PM
pSivida (PSDV) Given a $5.00 Price Target at B. RileypSivida (PSDV) Given a $5.00 Price Target at B. Riley
www.americanbankingnews.com - December 4 at 5:22 PM
pSivida Corp. (PSDV) Receives Average Rating of "Buy" from AnalystspSivida Corp. (PSDV) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - December 3 at 1:48 AM
pSivida (PSDV) Downgraded to "Strong Sell" at ValuEnginepSivida (PSDV) Downgraded to "Strong Sell" at ValuEngine
www.americanbankingnews.com - December 2 at 8:28 PM
ETFs with exposure to pSivida Corp. : November 30, 2017ETFs with exposure to pSivida Corp. : November 30, 2017
finance.yahoo.com - November 30 at 4:39 PM
pSivida Corp. :PSDV-US: Earnings Analysis: Q1, 2018 By the Numbers : November 29, 2017pSivida Corp. :PSDV-US: Earnings Analysis: Q1, 2018 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 10:20 AM
 Analysts Anticipate pSivida Corp. (PSDV) Will Post Quarterly Sales of $500,000.00 Analysts Anticipate pSivida Corp. (PSDV) Will Post Quarterly Sales of $500,000.00
www.americanbankingnews.com - November 23 at 12:32 PM
-$0.16 Earnings Per Share Expected for pSivida Corp. (PSDV) This Quarter-$0.16 Earnings Per Share Expected for pSivida Corp. (PSDV) This Quarter
www.americanbankingnews.com - November 21 at 3:26 AM
Edited Transcript of PSDV earnings conference call or presentation 7-Nov-17 1:30pm GMTEdited Transcript of PSDV earnings conference call or presentation 7-Nov-17 1:30pm GMT
finance.yahoo.com - November 9 at 11:54 AM
pSivida Corp.s (PSDV) "Buy" Rating Reaffirmed at HC WainwrightpSivida Corp.'s (PSDV) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - November 8 at 10:26 PM
pSivida Corp. (PSDV) Given Consensus Rating of "Buy" by AnalystspSivida Corp. (PSDV) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - November 8 at 11:58 AM
pSivida Corp. (PSDV) Releases  Earnings Results, Meets EstimatespSivida Corp. (PSDV) Releases Earnings Results, Meets Estimates
www.americanbankingnews.com - November 7 at 4:20 PM
pSivida Corp. Builds Momentum During First Quarter FY18; Continues Operating Milestone Execution - GlobeNewswire (press release)pSivida Corp. Builds Momentum During First Quarter FY18; Continues Operating Milestone Execution - GlobeNewswire (press release)
globenewswire.com - November 7 at 9:08 AM
pSivida Corp. Builds Momentum During First Quarter FY18; Continues Operating Milestone ExecutionpSivida Corp. Builds Momentum During First Quarter FY18; Continues Operating Milestone Execution
finance.yahoo.com - November 7 at 9:07 AM
pSivida Corp. to Host Earnings CallpSivida Corp. to Host Earnings Call
finance.yahoo.com - November 7 at 9:07 AM
PSivida reports 1Q lossPSivida reports 1Q loss
finance.yahoo.com - November 7 at 9:07 AM
ETFs with exposure to pSivida Corp. : November 3, 2017ETFs with exposure to pSivida Corp. : November 3, 2017
finance.yahoo.com - November 4 at 9:04 AM
pSivida Corp. (PSDV) Expected to Announce Quarterly Sales of $740,000.00pSivida Corp. (PSDV) Expected to Announce Quarterly Sales of $740,000.00
www.americanbankingnews.com - November 2 at 9:10 AM
-$0.15 EPS Expected for pSivida Corp. (PSDV) This Quarter-$0.15 EPS Expected for pSivida Corp. (PSDV) This Quarter
www.americanbankingnews.com - October 31 at 3:37 PM
Contrasting pSivida Corp. (PSDV) and Its CompetitorsContrasting pSivida Corp. (PSDV) and Its Competitors
www.americanbankingnews.com - October 31 at 1:06 PM

SEC Filings

pSivida (NASDAQ:PSDV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

pSivida (NASDAQ:PSDV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

pSivida (NASDAQ PSDV) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.